Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Form / Attachment / Pricing Sheet

This document, titled "Price Appendix FAQ," provides frequently asked questions and instructions for completing pricing appendices related to an opportunity. It clarifies how bidders should input pricing information for different categories of drugs and products.

• BPA (Blanket Purchase Agreement) Pricing: Instructions on filling out yellow cells in a spreadsheet, auto-population of data based on Package Size and Price per NDC, and how to indicate non-submission of a quote.
• ADP (non-FAMP Discount) Pricing: Guidance on inputting non-FAMP price and Current Annual Federal Ceiling Price, auto-population of subsequent rows, and calculation of Total Calculated Refund.
• ADP (WAC Discount) Pricing: Details on using WAC for products without a FCP, auto-population of WAC price, and calculation of Total Calculated Retail Refund per Package.
• General Instructions: All sections emphasize reading "Formulary Notes," filling only yellow cells, and contacting POCs for assistance or to request additional tables if submitting more than 10 NDCs.

This document is crucial for bidders preparing their pricing proposals. It outlines the specific format and method for entering pricing data, including how certain entries will be auto-calculated or highlighted to indicate specific submission choices (e.g., not submitting a quote). Understanding these instructions is essential for accurate proposal submission and to avoid errors.

Other / Unclassified

This document outlines the process for the DoD Formulary Placement of FDA Newly Approved Innovator Drugs, as clarified by a Final Rule published in the Federal Register on July 27, 2015. It details the procedures for evaluating and recommending tier placement for new innovator drugs on the uniform formulary.

• Drug Evaluation: The Pharmacy and Therapeutics (P&T) Committee evaluates FDA-approved medications under BLA or NDA with specific chemical types (Type 1, 2, 3, 4) and may consider other NDA chemical types.
• Placement Process: Drugs approved by the FDA on or after August 26, 2015, will initially be assigned a pending status and treated as non-formulary. Drugs approved less than 30 days before a P&T Committee meeting will be considered at the subsequent meeting.
• Cost-Effectiveness: The government will solicit Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (UF ADP) quotes for newly approved drugs to assess cost-effectiveness.
• Solicitation Windows: Manufacturers will have three solicitation windows to submit price concessions leading up to the P&T Committee meeting.
• Tier Designation: Drugs will be designated into Tier 1, 2, 3, or 4/Not Covered based on clinical and cost-effectiveness information.
• Information Posting: Drugs under review will be posted on the health.mil/pandt page approximately 30 days before the meeting.
• Distribution and Pricing Agreement (DAPA): Pharmaceutical manufacturers are not obligated to obtain a DAPA, but information on establishing one can be obtained from the Defense Logistics Agency (DLA).
• MTF Availability: Innovator drugs are generally designated as Tier 3 and not available at Military Treatment Facilities (MTFs) unless medical necessity is established by the prescriber. They are available through TMOP and retail pharmacies at a Tier 3 copay, or a 2nd tier copay if medical necessity is met.
• Presentations: DoD will not entertain innovator drug clinical presentations due to the volume of newly approved drugs.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) is for pharmaceutical agents to be considered for placement on the Department of War (DoW) Uniform Formulary (UF). The DoW aims to establish an effective and efficient pharmacy benefits program for the Military Health System (MHS). This process allows manufacturers to submit offers to reduce the DoW's cost for pharmaceutical agents.

• UF BPA Quotes: For prices applicable to Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP).

• UF ADP Quotes: For refunds applicable to pharmaceutical agents dispensed in the TRICARE retail network.

• NDC Price List: Must be submitted with quotes, containing prices per unit of measure and per NDC-11 package.

• Clinical and Cost Effectiveness Data: Information on drug properties, advantages over competitors, place in therapy, Minimum Clinically Important Difference (MCID), and patient-reported outcomes.

• Contract Type: Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs).

• Period of Performance: Agreements will be effective upon signature and continue until the drug class is reevaluated or terminated. Prices are valid for 180 days.

• Estimated Value: Not explicitly stated.

• Submission Steps: Download utilization dataset and NDC Price List, complete applicable pages and appendices, and submit signed quotes and NDC Price List.

• Evaluation Criteria: The DoW Pharmacy and Therapeutics (P&T) Committee will consider clinical effectiveness, cost effectiveness, UF BPA price quotes, and UF ADP refund quotes.

• Key Deadlines:

  • Posting Date: March 6, 2026
  • Pre-Quotation Teleconference: March 11, 2026
  • Quotes Due: March 26, 2026
  • Responses to Clinical Questions Due: March 26, 2026
  • P&T Committee Meeting: May 6-7, 2026

• No specific set-aside requirements are mentioned.

• Companies must have an existing FSS contract / Interim Agreement.

• A pre-quotation teleconference will be held on March 11, 2026.

• One-on-one appointments with the Industry Technical Liaison are available upon request.

• The document includes definitions, acronyms, and appendices detailing submission requirements for UF BPA and UF ADP.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for Cardiovascular Agents Miscellaneous, specifically for the May 2026 P&T Committee Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) based on non-FAMP (Non-Federal Average Manufacturer Price) and WAC (Wholesale Acquisition Cost) discounts. Bidders are instructed to submit a Quote Submission Checklist and executed signature pages along with their quote information.

• BPA Appendix: Details pricing for Cardiovascular Agents Miscellaneous, including NDC Number, Drug Name, Strength, Dosage Form, Package Size, and pricing scenarios (Uniform Formulary, Non-Formulary). It notes that "NO QUOTE" is indicated for certain scenarios and requires confirmation if a quote is not being submitted.
• ADP (non-FAMP Discount) Appendix: Outlines the Additional Discount Program based on non-FAMP. It includes columns for Non-FAMP Price of Drug Per FCP Package, Additional Offered Refund Per FCP Package, Current Annual Federal Ceiling Price Per FCP Package, Standard Refund Per FCP, and Total Calculated Retail Refund Per FCP Package. It also specifies that the quoted additional refund percentage remains static, but the annual non-FAMP and calculated refund may change yearly.
• ADP (WAC Discount) Appendix: Details the Additional Discount Program based on WAC. It includes columns for WAC Price of Drug, WAC Discount, and Total Calculated Retail Refund per Package. The WAC discount percentage is static for the agreement's life.
• Class Notes: Applicable to all sections, these notes state that agents will be reviewed at the P&T Committee meeting, Prior Authorization (PA) may apply, and agents may be considered for special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Agents with RFQs not submitted or selected may be designated non-step preferred.
• Quotes Due: March 26, 2026.

This document is crucial for bidders providing Cardiovascular Agents Miscellaneous. It outlines the specific pricing structures (BPA, non-FAMP discount, WAC discount), required submission components, and deadlines. Bidders must use this information to prepare their quotes and understand the pricing and discount expectations for participation in the TRICARE pharmacy benefit program. The "NO QUOTE" indicators and the requirement to confirm intent not to submit a quote are critical for bidders to address.

Forms / Attachments / Pricing Sheets

This document contains pricing information and discount program appendices related to Skeletal Muscle Relaxants and Combinations for the May 2026 P&T Meeting. It includes a Blanket Purchase Agreement (BPA) Appendix, an Additional Discount Program (ADP) Appendix (non-FAMP discount), and an ADP Appendix (WAC discount).

• BPA Appendix: Lists drug information, formulary scenarios, and indicates 'NO QUOTE' for specific scenarios, suggesting a focus on existing agreements or specific procurement paths.
• ADP (non-FAMP Discount) Appendix: Details calculations for total retail refunds based on non-FAMP prices and offered refunds. It outlines scenarios for Tier 2 and Tier 3 drugs.
• ADP (WAC Discount) Appendix: Outlines calculations for retail refunds based on Wholesale Acquisition Cost (WAC) discounts. It also details scenarios for Tier 2 and Tier 3 drugs.
• Class Notes: Applicable to all sections, these notes indicate that the agents will be reviewed at the May 6-7, 2026 P&T Committee meeting. Prior Authorization (PA) may apply, and agents could be considered for special reimbursement methods or complete exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected for RFQ may be designated non-step preferred.
• Notes to Manufacturers: Emphasizes the need to submit the Quote Submission Checklist and fully executed signature pages.

This document is crucial for manufacturers and vendors of Skeletal Muscle Relaxants and Combinations. It provides specific pricing structures, discount program details (both non-FAMP and WAC), and deadlines for quotes (March 26, 2026). The 'NO QUOTE' indications in the BPA section and the detailed refund calculations in the ADP sections are critical for understanding pricing strategies and potential participation. The P&T meeting date and class notes highlight upcoming reviews and potential policy changes affecting these drug categories.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for antibiotics, specifically Beta-lactams, related to the May 2026 P&T Committee Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP and WAC discounts, and associated pricing scenarios.

• BPA Appendix: Lists antibiotic (Beta-lactams) NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing scenarios. It indicates "NO QUOTE" for certain scenarios and requires confirmation if no quote is submitted.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations for antibiotics (Beta-lactams) based on non-FAMP (non-Federal Acquisition Regulation) prices. It outlines formulas for calculating total retail refunds and specifies a quote due date of March 26, 2026.
• ADP (WAC Discount) Appendix: Provides pricing and refund information based on Wholesale Acquisition Cost (WAC) for antibiotics (Beta-lactams). It defines WAC discount calculations and notes that the quoted discount percentage remains static.
• Class Notes: Applicable to all sections, these notes state that agents will be reviewed at the P&T Committee meeting, Prior Authorization (PA) may apply, and agents may be considered for special reimbursement methods or exclusion. Step Therapy Addendum notes that agents without submitted or selected RFQs may be designated non-step preferred.
• Notes to Manufacturers: Reminds manufacturers to submit the Quote Submission Checklist and executed signature pages with quote information.

This document is crucial for potential bidders offering antibiotics, particularly Beta-lactams. It outlines the pricing structure, discount programs (non-FAMP and WAC), and submission requirements for quotes. Bidders must understand the formulary status, pricing scenarios, refund calculations, and the P&T meeting schedule (May 6-7, 2026) with a quote due date of March 26, 2026, to prepare accurate and competitive proposals.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Calcium Channel Blocking Agents, relevant for the May 2026 P&T Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP and WAC discounts, and related formulary scenarios.

• BPA Appendix: Lists Calcium Channel Blocking Agents, their NDC numbers, strengths, dosage forms, and package sizes. It outlines "Formulary Scenarios" (Uniform Formulary, Non-Formulary) and indicates "NO QUOTE" for specific conditions, with a deadline of March 26, 2026.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations based on non-FAMP (Non-Federal Average Manufacturer Price) and Federal Ceiling Price (FCP). It includes scenarios for Tier 2 and Tier 3 drugs, with a quote deadline of March 26, 2026.
• ADP (WAC Discount) Appendix: Outlines pricing and refund calculations based on Wholesale Acquisition Cost (WAC). It specifies scenarios for Tier 2 and Tier 3 drugs and includes a quote deadline of March 26, 2026.
• Class Notes: Applicable to all sections, these notes mention that agents will be reviewed at the P&T Committee meeting, Prior Authorization (PA) may apply, and agents could be considered for special reimbursement methods or exclusion. Agents not submitted or selected may be designated non-step preferred.
• Manufacturer Notes: Reminders to submit the Quote Submission Checklist and executed signature pages with quote information.

This document is crucial for manufacturers of Calcium Channel Blocking Agents. It provides specific pricing structures, discount program details (non-FAMP and WAC), formulary classifications, and submission requirements. Bidders must review the "Formulary Scenarios" and "Quotes due" dates (March 26, 2026) to understand pricing expectations and submission deadlines for potential inclusion in the TRICARE pharmacy benefit program.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Phosphodiesterase-5 Inhibitors used for Erectile Dysfunction. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP and WAC discounts, and related pricing scenarios.

• BPA Appendix: Lists drug names, strengths, dosage forms, and package sizes. It outlines "Formulary Scenarios" with "Uniform Formulary" and "Non-Formulary" categories, indicating "NO QUOTE" for specific NDC numbers. It also specifies a P&T Committee Meeting date of May 6-7, 2026, and a quotes due date of March 26, 2026.
• ADP (non-FAMP Discount) Appendix: Details pricing based on non-FAMP (non-Federal Acquisition Regulation Part 13) prices per Federal Ceiling Price (FCP) package. It includes columns for "Non-FAMP Price of Drug Per FCP Package," "Additional Offered Refund Per FCP Package," and "Current Annual Federal Ceiling Price Per FCP Package." It also specifies "Tier 2" and "Tier 3" formulary categories.
• ADP (WAC Discount) Appendix: Outlines pricing based on Wholesale Acquisition Cost (WAC). It includes "WAC Price of Drug," "WAC Discount," and "Total Calculated Retail Refund per Package." Similar to the non-FAMP appendix, it specifies "Tier 2" and "Tier 3" formulary categories.
• General Notes: All appendices mention that agents will be reviewed at the May 6-7, 2026 P&T Committee meeting, and Prior Authorization (PA) may apply. Manufacturers are reminded to submit a Quote Submission Checklist and executed signature pages. The quotes are due by March 26, 2026.

This document is crucial for potential bidders offering Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. It provides the framework for submitting pricing quotes, outlines the specific drug categories and NDC numbers of interest, and details the discount structures (non-FAMP and WAC) that will be applied. Bidders must carefully review the "Formulary Scenarios" and pricing requirements to determine their quoting strategy and ensure timely submission by the March 26, 2026 deadline.

Form / Attachment / Pricing Sheet

This document contains pricing information and details related to the Uniform Formulary (UF) Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Electrolyte-Mineral-Trace Element Replacement drugs. It outlines pricing structures and requirements for manufacturers submitting quotes.

• P&T Committee Meeting: May 6-7, 2026
• Quotes Due: March 26, 2026
• Drug Class: Electrolyte-Mineral-Trace Element Replacement
• Pricing Structures:
  • BPA Appendix: Details pricing per NDC, strength, dosage form, and package size for Military Treatment Facility & Mail Order. Includes "Formulary Scenarios" (Uniform Formulary, Non-Formulary) with "Price per Unit" and "Price per NDC" fields, many marked as "NO QUOTE" indicating potential non-submission or selection.
  • ADP (non-FAMP Discount) Appendix: Outlines pricing for TRICARE Retail Refund, including "Non-FAMP Price of Drug Per FCP Package," "Additional Offered Refund Per FCP Package," "Current Annual Federal Ceiling Price Per FCP Package," and "Total Calculated Retail Refund Per FCP Package." Applicable to Tier 1 and Tier 2 formulary categories.
  • ADP (WAC Discount) Appendix: Details pricing based on Wholesale Acquisition Cost (WAC) for TRICARE Retail Refund. Includes "WAC Price of Drug," "WAC Discount," and "Total Calculated Retail Refund per Package." Applicable to Tier 2 and Tier 3 formulary categories.
• Class Notes: Agents reviewed at P&T Committee meetings; Prior Authorization (PA) may apply. Potential for special reimbursement methods, preferential status (Tier 1), or exclusion from the TRICARE pharmacy benefit program. Step Therapy Addendum notes that agents with unsubmitted or unselected RFQs may be designated non-step preferred.
• Manufacturer Notes: Emphasizes submitting the Quote Submission Checklist and fully executed signature pages. Clarifies pricing per unit of measure is consistent across package sizes within a dispensing venue. Explains calculation methods for refunds based on FCP and WAC.

This document is critical for manufacturers of Electrolyte-Mineral-Trace Element Replacement drugs. It specifies the deadlines for quote submissions (March 26, 2026) and outlines the various pricing models (BPA, non-FAMP discount, WAC discount) and formulary scenarios that will be used for reimbursement and potential contract awards. Bidders must carefully review the pricing structures and class notes to understand the requirements and potential financial implications for their products.